TickerFacts.

Maze Therapeutics, Inc. (MAZE): Shareholders' Equity

Annual figures by period end, from SEC filings.

$354.97M
As of 2025-12-31
$453.12M
As of 2026-06-30
2024-12-31: -$311.18M2025-12-31: $354.97M$354.97M
2024-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$354.97Mn/m2026-03-25, Balance as of period end
2024-12-31-$311.18Mn/a2026-03-25, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Maze Therapeutics, Inc. (MAZE)2025-12-31$354.97Mn/m
Scholar Rock Holding Corp (SRRK)2025-12-31$245.49M-33.4%
Allogene Therapeutics, Inc. (ALLO)2025-12-31$292.54M-30.7%
Sana Biotechnology, Inc. (SANA)2025-12-31$160.88M-35.8%
Scilex Holding Co (SCLX)2025-12-31-$207.78Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31$256.59M+18.8%
Cullinan Therapeutics, Inc. (CGEM)2025-12-31$408.73M-30.8%
Kodiak Sciences Inc. (KOD)2025-12-31$157.38M+4.7%
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31$233.06M+4.5%

Compare MAZE, SRRK, ALLO, SANA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗